Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.94 and traded as high as $5.81. Cumberland Pharmaceuticals shares last traded at $5.67, with a volume of 28,570 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Wall Street Zen lowered shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25. The company has a market cap of $83.89 million, a PE ratio of -11.43 and a beta of 0.09. The business’s fifty day moving average is $4.56 and its 200-day moving average is $3.95.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $9.13 million for the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its holdings in shares of Cumberland Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock worth $898,000 after buying an additional 4,081 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after buying an additional 4,200 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 5,653 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Cumberland Pharmaceuticals in the second quarter worth approximately $34,000. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.